

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/035206 A1

(51) International Patent Classification:

A01K 67/0275 (2024.01) *C12N 15/54* (2006.01)
A61K 49/00 (2006.01) *C12N 15/62* (2006.01)
C12N 5/10 (2006.01) *C12N 15/85* (2006.01)
C12N 9/00 (2006.01) *C12N 15/90* (2006.01)
C12N 9/10 (2006.01) *C12Q 1/68* (2018.01)
C12N 15/09 (2006.01) *C40B 30/06* (2006.01)
C12N 15/52 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(21) International Application Number:

PCT/CA2024/051048

(22) International Filing Date:

09 August 2024 (09.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/532,144 11 August 2023 (11.08.2023) US

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(71) Applicant: **MED-LIFE DISCOVERIES LP** [CA/CA];
407-15 Innovation Blvd, Saskatoon, Saskatchewan S7N
2X8 (CA).

(72) Inventors: **SMITH, Tara**; 351 Childers Crescent, Saska-
toon, Saskatchewan S7L 4L1 (CA). **RITCHIE, Shawn**;
1019 Brookhurst Crescent, Saskatoon, Saskatchewan S7V
1G6 (CA).

(74) Agent: **NEWTON, Trevor** et al.; 160 Elgin Street, Suite
2600, Ottawa, Ontario K1P 1C3 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ANIMAL MODELS OF POSTNATAL CONDITIONS ASSOCIATED WITH REDUCED LEVELS OF PLASMALOGEN

(57) Abstract: The invention describes a transgenic, non-human animal model, for testing post-natal, conditionally inducible plasmalogen deficiency. The animal model's genome is equipped with a gene that is capable of regulating the plasmalogen biosynthetic pathway, where the gene has a regulatory region. Within the regulatory region there is at least one conditionally inducible gene editing site that blocks the expression of the gene when edited. The genome also has a nucleic acid editing sequence integrated at a separate locus from the gene which encodes a gene product. The gene product edits the gene editing site when conditionally induced that eventually down-regulates or disrupts the plasmalogen biosynthetic pathway. Methods and uses involving the transgenic, non-human animal model are also provided.



WO 2025/035206 A1